TY - JOUR
T1 - Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017
AU - Krone, Manuel
AU - Gray, Steve
AU - Abad, Raquel
AU - Skoczyńska, Anna
AU - Stefanelli, Paola
AU - van der Ende, Arie
AU - Tzanakaki, Georgina
AU - Mölling, Paula
AU - Simões, Maria João
AU - Křížová, Pavla
AU - Emonet, Stéphane
AU - Caugant, Dominique A.
AU - Toropainen, Maija
AU - Vazquez, Julio
AU - Waśko, Izabela
AU - Knol, Mirjam J.
AU - Jacobsson, Susanne
AU - Bettencourt, C. lia Rodrigues
AU - Musilek, Martin
AU - Born, Rita
AU - Vogel, Ulrich
AU - Borrow, Ray
PY - 2019
Y1 - 2019
N2 - Background: The total incidence of invasive meningococcal disease (IMD) in Europe has been declining in recent years; however, a rising incidence due to serogroup W (MenW), predominantly sequence type 11 (ST-11), clonal complex 11 (cc11), was reported in some European countries. Aim: The aim of this study was to compile the most recent laboratory surveillance data on MenW IMD from several European countries to assess recent trends in Europe. Methods: In this observational, retrospective study, IMD surveillance data collected from 2013–17 by national reference laboratories and surveillance units from 13 European countries were analysed using descriptive statistics. Results: The overall incidence of IMD has been stable during the study period. Incidence of MenW IMD per 100,000 population (2013: 0.03; 2014: 0.05; 2015: 0.08; 2016: 0.11; 2017: 0.11) and the proportion of this serogroup among all invasive cases (2013: 5% (116/2,216); 2014: 9% (161/1,761); 2015: 13% (271/2,074); 2016: 17% (388/2,222); 2017: 19% (393/2,112)) continuously increased. The most affected countries were England, the Netherlands, Switzerland and Sweden. MenW was more frequent in older age groups (≥ 45 years), while the proportion in children (< 15 years) was lower than in other age groups. Of the culture-confirmed MenW IMD cases, 80% (615/767) were caused by hypervirulent cc11. Conclusion: During the years 2013–17, an increase in MenW IMD, mainly caused by MenW cc11, was observed in the majority of European countries. Given the unpredictable nature of meningococcal spread and the epidemiological potential of cc11, European countries may consider preventive strategies adapted to their contexts.
AB - Background: The total incidence of invasive meningococcal disease (IMD) in Europe has been declining in recent years; however, a rising incidence due to serogroup W (MenW), predominantly sequence type 11 (ST-11), clonal complex 11 (cc11), was reported in some European countries. Aim: The aim of this study was to compile the most recent laboratory surveillance data on MenW IMD from several European countries to assess recent trends in Europe. Methods: In this observational, retrospective study, IMD surveillance data collected from 2013–17 by national reference laboratories and surveillance units from 13 European countries were analysed using descriptive statistics. Results: The overall incidence of IMD has been stable during the study period. Incidence of MenW IMD per 100,000 population (2013: 0.03; 2014: 0.05; 2015: 0.08; 2016: 0.11; 2017: 0.11) and the proportion of this serogroup among all invasive cases (2013: 5% (116/2,216); 2014: 9% (161/1,761); 2015: 13% (271/2,074); 2016: 17% (388/2,222); 2017: 19% (393/2,112)) continuously increased. The most affected countries were England, the Netherlands, Switzerland and Sweden. MenW was more frequent in older age groups (≥ 45 years), while the proportion in children (< 15 years) was lower than in other age groups. Of the culture-confirmed MenW IMD cases, 80% (615/767) were caused by hypervirulent cc11. Conclusion: During the years 2013–17, an increase in MenW IMD, mainly caused by MenW cc11, was observed in the majority of European countries. Given the unpredictable nature of meningococcal spread and the epidemiological potential of cc11, European countries may consider preventive strategies adapted to their contexts.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064220536&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30968827
U2 - https://doi.org/10.2807/1560-7917.ES.2019.24.14.1800245
DO - https://doi.org/10.2807/1560-7917.ES.2019.24.14.1800245
M3 - Article
C2 - 30968827
SN - 1025-496X
VL - 24
JO - Euro surveillance
JF - Euro surveillance
IS - 14
M1 - 1800245
ER -